MetaCap

Nautilus Biotechnology (NAUT) vs Revvity (RVTY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Revvity (RVTY) has outperformed Nautilus Biotechnology (NAUT) over the past year, gaining 47.8% versus a loss of 5.4%. Over five years, RVTY leads with a -20.7% price change compared with -56.4% for NAUT. Revvity is the larger company by market cap ($16.21 billion vs $270.0 million), about 60.0 times the size.

Revvity pays a dividend yielding 0.19%, while Nautilus Biotechnology does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NAUT-5.36%RVTY+47.78%
+83%+7%-69%
Nov 21, 20251 yearNov 20, 2026
NAUT-57.68%RVTY-23.09%
+26%-33%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NAUT versus RVTY key metrics
MetricNAUTRVTY
Share price$2.12$145.22
Market cap$270.03M$16.21B
1-day change-2.30%-4.20%
YTD return+8.72%+50.10%
1-year return-5.36%+47.78%
5-year return-56.38%-20.68%
P/E ratio (TTM)—64.54
Forward P/E—24.38
EPS (TTM)$-0.46$2.25
Dividend yield0.00%0.19%
Annual dividend$0.00$0.28
Revenue (latest FY)—$2.86B
Revenue growth (YoY)—+3.67%
Net income (latest FY)$-59.00M$241.20M
Operating margin—12.49%
Net margin—8.45%
52-week high$4.31$171.74
52-week low$0.841$81.22
Distance from 52-week high-50.81%-15.44%
Analyst consensusnonebuy
Avg. price target upside+88.68%+18.03%
Average volume6.25M1.91M
Shares outstanding127.37M111.64M
Employees12811,000
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Revvity is about 60.0 times larger than Nautilus Biotechnology by market value ($16.21B vs $270.03M).
  • RVTY has outperformed NAUT by 53.1 percentage points over the past year.

About Nautilus Biotechnology

NAUT stock →

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.

Industrials · Biotechnology: Laboratory Analytical Instruments · 128 employees

About Revvity

RVTY stock →

Revvity, Inc. provides health sciences solutions, technologies, and services.

Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees

NAUT vs RVTY FAQ

Which is bigger, Nautilus Biotechnology or Revvity?

Revvity (RVTY) is larger, with a market capitalization of $16.21B compared with $270.03M for Nautilus Biotechnology (NAUT).

Which stock has performed better over the past year, NAUT or RVTY?

RVTY returned +47.78% over the past 12 months, compared with -5.36% for NAUT (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Nautilus Biotechnology or Revvity?

Revvity pays a dividend yielding 0.19%, while Nautilus Biotechnology does not currently pay a regular dividend.

Are Nautilus Biotechnology and Revvity in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons